不同浓度抗磷脂抗体及TNF-α对内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响
|
摘要
抗磷脂综合征(Antiphospholipid syndrome, APS)是一种系统性自身免疫性疾病,血清抗磷脂抗体(antiphospholipid antibody, aPL)阳性和血栓前状态为APS的两大重要血清学特征,这种血清学特征与栓塞的发生和病理妊娠密切相关。APS发病机制不明,血栓形成一直以来被认为是APS发病的重要因素,而内皮细胞活化则是血栓形成的重要原因。抗体浓度及感染与APS的发病及预后关系密切,国内外学者普遍认为中高浓度情况下,浓度越高、病情越重、预后越差,感染则可加重APS病情。导致此种现象的机制未明,内皮细胞是否参与其中,国内未见此方面研究。
aPL活化内皮细胞具有特定的信号传导通路,并非简单的磷脂结合途径。大部分aPL直接与β2糖蛋白I (β2GPI)结合,aPL/β2GPI复合物进一步结合于细胞表面。目前细胞的Toll样受体(TLR)信号传导通路尤其是TLR2和TLR4信号通路是研究的热点,国外研究发现TLR2参与aPL活化内皮细胞的信号传导中,而TLR4是否参与其中存在争议,国内未见相关研究。
内皮细胞活化后可分泌多种细胞因子,本文选择E-选择素(SELE)、单核细胞趋化蛋白1(MCP-1)、白细胞介素6(IL-6)和白细胞介素8(IL-8)四种常用且敏感的指标用以监测内皮细胞活化后的分泌功能,其中E-选择素mRNA表达量增加或降低时,其蛋白的表达水平发生相应的上调或下调,因此本文分别从mRNA及蛋白水平对E-选择素的表达进行检测,若二者的表达均增加或减少,则从一方面说明了实验结果正确性。本文所采用的aPL为从APS患者血清中提纯的IgG,为排除正常IgG对实验的影响,选择正常人群血清中提纯的IgG作为正常对照。
本文拟分为三个部分,第一部分体外培养脐静脉内皮细胞(human umbilical vein endothelial cell, HUVEC),分别用正常对照IgG及不同浓度APS患者IgG刺激细胞,探讨不同浓度aPL对内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响。第二部分探讨TNF-α干预下内皮细胞TLR2/4表达情况其TNF-α干预下aPL对血管内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响,进一步研究APS血管内皮细胞活化的机制,并为治疗APS提供新靶点。第三部分通过研究卡介菌多糖核酸(BCG-PSN)对aPL刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1的影响,探讨BCG-PSN是否有可能成为治疗APS的新选择药物。
第一章不同浓度抗磷脂抗体对内皮细胞分泌E-选择素、IL-6、IL-8. MCP-1影响的研究
目的：观察不同浓度抗磷脂抗体对血管内皮细胞分泌功能的影响。
方法：体外培养人脐静脉内皮细胞,分别用PBS(空白组)、正常人血清提取的IgG(正常对照组)和不同浓度APS患者血清提取的IgG (APS IgG)(5%、10%和20%)干预细胞。采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达,采用Western blot检测内皮细胞TLR2和TLR4的表达。
结果：正常对照组内皮细胞SELE、MCP-1、IL-6和IL-8表达量与空白组比较,无统计学差异(p>0.05); APSIgG可诱导内皮细胞SELE. MCP-1、IL-6和IL-8表达增加,与空白组、正常对照组比较及不同浓度APS IgG组之间两两比较,差异有显著统计学意义(p<0.01)；空白组、正常对照组及5%APS IgG组两两比较,内皮细胞TLR2表达量无明显差异(p>0.05),10%及20%APS IgG组TLR2表达量与空白组及正常对照组比较及两组之间比较,差异有统计学意义(p<0.05)；各组之间TLR4表达量无明显差异(p>0.05)。
结论：抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1增加且作用具有浓度依赖性,浓度越高,作用越强。
第二章TNF-a对内皮细胞TLR2/4表达的影响及APS发病机制的研究
目的：
探讨TNF-a干预下aPL刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1的情况及TLR2和TLR4在抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1中的作用。
方法：
(1)一半细胞采用肿瘤坏死因子a (TNF-a)预刺激24小时后去除刺激因素8小时,一半细胞未经TNF-a预刺激但余处理相同,收集一部分TNF-a预刺激及未预刺激细胞,采用Western blot检测TNF-a预处理对内皮细胞TLR2和TLR4表达的影响,余下的TNF-a预刺激及未预刺激细胞分别用脂磷壁酸(LTA)、正常对照IgG及不同浓度APS IgG(5%、10%和20%)进行干预,采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达；(2)分别加入抗-TLR2或(和)抗-TLR4阻断抗体阻断TLR2或(和)TLR4信号传导通路后,用20%浓度APS IgG干预细胞,采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达。
结果：
经TNF-a预刺激后,细胞TLR2表达量较未经TNF-a预刺激细胞明显增加,差异有统计学意义(p<0.01),TLR4表达量无明显变化(p>0.05)；经TNF-a预处理及未预处理细胞均用TLR2特异性激动剂LTA进行干预,经TNF-a预处理组SELE、MCP-1、IL-6和IL-8表达量较未经TNF-a预处理组明显增高,差异有统计学意义(p<0.01)：经TNF-a预刺激后再用同浓度APS IgG干预细胞,SELE、 MCP-1、IL-6和IL-8表达量与仅用APS IgG干预组比较明显增高,差异有统计学意义(p<0.01),不同浓度APS IgG组与正常对照组四组之间两两比较,差异均有统计学意义(p<0.01)；
抗-TLR2+APS IgG组及抗-TLR2+抗-TLR4组内皮细胞SELE、 MCP-1、IL-6和IL-8表达量,较APS IgG组明显降低,差异有统计学意义(p<0.01)；抗-TLR4+APS IgG组内皮细胞SELE. MCP-1、 IL-6和IL-8表达量,与APS IgG组比较无明显改变,差异无统计学意义(p>0.05)。
结论：
(1)TNF-a干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、 IL-8、MCP-1的作用增强。
(2)抗磷脂抗体通过TLR2信号传导通路刺激内皮细胞使其E-选择素、IL-6、IL-8、MCP-1分泌增加。
第三章卡介菌多糖核酸对抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响
目的：
探讨卡介菌多糖核酸(BCG-PSN)干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的情况。
方法：
用APS患者血清提取的IgG处理内皮细胞,APS IgG处理前预先加入不同浓度BCG-PSN(0、25、50和100μg/ml),采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素表达,采用ELISA测定细胞分泌MCP-1、IL-6和IL-8的表达。
结果：
BCG-PSN干预下APS IgG所诱导的内皮细胞SELE.MCP-1、IL-6和IL-8表达明显降低,APS IgG组及不同浓度BCG-PSN组之间两两比较,差异均有统计学意义(p<0.01)。
结论：
卡介菌多糖核酸干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的作用减弱,提示它可以用于APS的治疗。
Antiphospholipid syndrome (APS) is a systemic autoimmune disease, the presence of antiphospholipid antibody (aPL) in the serum and generalized prothrombotic state are the two major characteristics, and this serological characteristics are closely related to embolism and pathological pregnancy. The pathogenesis of APS is still unclear, prothromboticstate is one of the important factors, and the important factor required for the formation of prothromboticstate is endothelial cells'damage and activation. About the relation between the concentration of aPL, infection and the incidence and prognosis of APS, some foreign scholars believe that the higher the concentration, the worse the prognosis, infection can make APS worse. What makes this phenomenon? Is the activation of endothelial cell involved in it? No such research has been seen in China.
One of the major receptors for aPL is β2-glycoprotein I (β2GPI). aPL/β2GPI complex further binds to annexin A2, then combines with phospholipids on the cell membrane, however, annexin A2does not have the transmembrane structure, cell signal cannot be conducted. Many researches have been focused on toll-like receptor (TLR) signaling pathway and found that TLR2mediated the signal transduction, disagreement was existed about the role of TLR4, no such research in China.
After activation, the synthesis and secretion of adhesion molecule such as E-selectin (SELE) significantly increased, a number of inflammatory cytokines such as interleukin-1β(IL-1β), interleukin-6(IL-6),interleukin-8(IL-8), tumor necrosis factor-a (TNF-a), monocyte chemoattractant protein-1(MCP-1) also increased significantly, resulting in a proinflammatory and procoagulant state. Among them, E-selectin、 IL-6、IL-8、MCP-1are the most sensitive and frequently used factors in monitoring the endothelial cells'activation extent. The consistent change of SELE mRNA and pretein levels means the correctness of the experimental results. Limited by the experimental techniques and conditions, the aPL used in our research is the purified IgG from APS patients, the purified IgG from normal person was used as normal control to exclude the possible effects of the normal types of IgG.
The paper is divided into three parts:the first part was to investigate the effects of various titers of aPL on endothelial cells. Culturing human umbilical vein endothelial cells (HUVECs) in vitro, stimulating them with purified IgG proteins from APS or normal non-pregnant women. Endothelial cell secretion function was assessed by measuring mRNA and protein levels of E-selectin by the means of real-time fluorescent quantitative-polymerase chain reaction (RT-PCR) and flow cytometry (FACS), the protein levels of MCP-1, IL-6and IL-8were measured by mean of enzyme-linked immunosorbent assay (ELISA), TLR2and TLR4 were measured by Western blot. The second part was to study the effect of TNF-α and the role of TLR2and TLR4in activation of the endothelial cells by aPL. By blocking TLR2or (and) TLR4signal transduction way, we study the role of TLR2/4directly. The third part was about investigating the effects of BCG polysaccharides nucleic acid (BCG-PSN) in activation of endothelial cells by aPL, to explore whether BCG-PSN can be used in APS.
Chapter1
Secretion of E-selectin, IL-6, IL-8and MCP-1by endothelial cell stimulated by various titers of antiphospholipid antibody
Objective:
To study the expression of E-selectin, IL-6, IL-8, MCP-1on endothelial cell when stimulated by various titers of aPLs.
Methods:
HUVECs were cultured in vitro, and stimulated with aPLs from APS (5%,10%,20%) or normal non-pregnant women. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA, Western blot analysis was used to measure the protein levels of TLR2and TLR4.
Results:
Stimulated by aPL showed a significant increase in SELE, IL-6, IL-8, MCP-1expression, comparing every two groups of blank, normal control or aPL (5%,10%,20%) groups, p<0.01.
There are no significant difference on TLR2expression between the groups of blank, normal and5%aPL(p>0.05), TLR2expression in10%and20%aPL groups were significantly increased compared with the blank and normal control groups or with each other (p<0.05). aPL has no effect on the expression of TLR4(p>0.05)
Conclusions:
Expression of E-selectin, IL-6, IL-8and MCP-1on endothelial cell increased when stimulated by aPL, the higher the antibody concentration, the higher the expression.
Chapter2
The role of TNF-a, TLR2and TLR4in activation of endothelial cell by antiphospholipid antibodiy
Objective:
To investigate the role of TNF-a, TLR2/4in secretion function of endothelial cell when stimulated by antiphospholipid antibodiy.
Methods:
(1) HUVECs were cultured in vitro, part of them were stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, collecting some TNF-pretreated and non-pretreated cells, using Western blot analysis to measure the protein levels of TLR2and TLR4. The rest cells were stimulated with LTA or aPLs from APS women. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA;(2) HUVECs were cultured in vitro and stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, then treated with aPL, Anti-TLR2antibodies or/and anti-TLR4antibodies were used before adding aPL to block TLR2or/and TLR4signal conduct pathways. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8 were measured by mean of ELISA.
Results:
After pre-stimulation by TNF-a, the TLR2expression on HUVEC was significantly increased compared with the non-pretreated group (p<0.01), the TLR4expression had no change (p>0.05). stimulated by LTA, the specific agonist of TLR2, the expression of SELE, IL-6, IL-8, MCP-1were significantly increased in TNF-apretreated group compared with the non-pretreated group (p<0.01). Under the same concentration of aPL, the expression of SELE, IL-6, IL-8, MCP-1in TNF-pretreated group were significantly higher than non-pretreated group (p<0.01).
Blocking TLR2signal conduct pathways significantly attenuated the expression of SELE, IL-6, IL-8, MCP-1expression on HUVEC stimulated by aPL (p<0.01). blocking TLR4did not have significant effect on the expression of SELE, IL-6, IL-8, MCP-1stimulated by aPL HUVEC (p>0.05).
Conclusions:
(1) TNF-apre-treated endothelial cell secretes more SELE, IL-6, IL-8, MCP-1than non-pre-treated cell when stimulated by aPL.
(2) Antiphospholipid antibodies activate endothelial cell via TLR2signal transduction pathways.
Chapter3
The impact of BCG-polysaccharides nucleic acid on E-selectin, IL-6, IL-8and MCP-1expression on endothelial cell stimulated by antiphospholipid antibody
Objective:
To investigate the impact of BCG-polysaccharides nucleic acid (BCG-PSN) on secretion function of endothelial cell stimulated by antiphospholipid antibody.
Methods:
HUVECs were cultured in vitro, and stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, then treated with20%of APS aPLs, APS aPLs treated groups were also treated with different concentrations of BCG-PSN (0,25,50and100μg/ml). Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA.
Results:
APS IgG induced endothelial cells' SELE, IL-6, IL-8, MCP-1expression increasing, while the intervention of BCG-PSN attenuated APS IgG-induced SELE, IL-6, IL-8, MCP-1expression, compared any two of BCG-PSN groups (0,25,50and100μg/ml), the differences were statistically significant (p<0.01).
Conclusion:
Antiphospholipid antibody induced secretion of E-selection, IL-6, IL-8, MCP-1on endothelial cell decreased when interfered by BCG-polysaccharides nucleic acid, suggesting that it may be useful for the treatment of APS.
aPL活化内皮细胞具有特定的信号传导通路,并非简单的磷脂结合途径。大部分aPL直接与β2糖蛋白I (β2GPI)结合,aPL/β2GPI复合物进一步结合于细胞表面。目前细胞的Toll样受体(TLR)信号传导通路尤其是TLR2和TLR4信号通路是研究的热点,国外研究发现TLR2参与aPL活化内皮细胞的信号传导中,而TLR4是否参与其中存在争议,国内未见相关研究。
内皮细胞活化后可分泌多种细胞因子,本文选择E-选择素(SELE)、单核细胞趋化蛋白1(MCP-1)、白细胞介素6(IL-6)和白细胞介素8(IL-8)四种常用且敏感的指标用以监测内皮细胞活化后的分泌功能,其中E-选择素mRNA表达量增加或降低时,其蛋白的表达水平发生相应的上调或下调,因此本文分别从mRNA及蛋白水平对E-选择素的表达进行检测,若二者的表达均增加或减少,则从一方面说明了实验结果正确性。本文所采用的aPL为从APS患者血清中提纯的IgG,为排除正常IgG对实验的影响,选择正常人群血清中提纯的IgG作为正常对照。
本文拟分为三个部分,第一部分体外培养脐静脉内皮细胞(human umbilical vein endothelial cell, HUVEC),分别用正常对照IgG及不同浓度APS患者IgG刺激细胞,探讨不同浓度aPL对内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响。第二部分探讨TNF-α干预下内皮细胞TLR2/4表达情况其TNF-α干预下aPL对血管内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响,进一步研究APS血管内皮细胞活化的机制,并为治疗APS提供新靶点。第三部分通过研究卡介菌多糖核酸(BCG-PSN)对aPL刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1的影响,探讨BCG-PSN是否有可能成为治疗APS的新选择药物。
第一章不同浓度抗磷脂抗体对内皮细胞分泌E-选择素、IL-6、IL-8. MCP-1影响的研究
目的：观察不同浓度抗磷脂抗体对血管内皮细胞分泌功能的影响。
方法：体外培养人脐静脉内皮细胞,分别用PBS(空白组)、正常人血清提取的IgG(正常对照组)和不同浓度APS患者血清提取的IgG (APS IgG)(5%、10%和20%)干预细胞。采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达,采用Western blot检测内皮细胞TLR2和TLR4的表达。
结果：正常对照组内皮细胞SELE、MCP-1、IL-6和IL-8表达量与空白组比较,无统计学差异(p>0.05); APSIgG可诱导内皮细胞SELE. MCP-1、IL-6和IL-8表达增加,与空白组、正常对照组比较及不同浓度APS IgG组之间两两比较,差异有显著统计学意义(p<0.01)；空白组、正常对照组及5%APS IgG组两两比较,内皮细胞TLR2表达量无明显差异(p>0.05),10%及20%APS IgG组TLR2表达量与空白组及正常对照组比较及两组之间比较,差异有统计学意义(p<0.05)；各组之间TLR4表达量无明显差异(p>0.05)。
结论：抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1增加且作用具有浓度依赖性,浓度越高,作用越强。
第二章TNF-a对内皮细胞TLR2/4表达的影响及APS发病机制的研究
目的：
探讨TNF-a干预下aPL刺激内皮细胞分泌E-选择素、IL-6、IL-8、 MCP-1的情况及TLR2和TLR4在抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1中的作用。
方法：
(1)一半细胞采用肿瘤坏死因子a (TNF-a)预刺激24小时后去除刺激因素8小时,一半细胞未经TNF-a预刺激但余处理相同,收集一部分TNF-a预刺激及未预刺激细胞,采用Western blot检测TNF-a预处理对内皮细胞TLR2和TLR4表达的影响,余下的TNF-a预刺激及未预刺激细胞分别用脂磷壁酸(LTA)、正常对照IgG及不同浓度APS IgG(5%、10%和20%)进行干预,采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达；(2)分别加入抗-TLR2或(和)抗-TLR4阻断抗体阻断TLR2或(和)TLR4信号传导通路后,用20%浓度APS IgG干预细胞,采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素的表达,采用酶联免疫吸附试验测定细胞分泌MCP-1、IL-6和IL-8的表达。
结果：
经TNF-a预刺激后,细胞TLR2表达量较未经TNF-a预刺激细胞明显增加,差异有统计学意义(p<0.01),TLR4表达量无明显变化(p>0.05)；经TNF-a预处理及未预处理细胞均用TLR2特异性激动剂LTA进行干预,经TNF-a预处理组SELE、MCP-1、IL-6和IL-8表达量较未经TNF-a预处理组明显增高,差异有统计学意义(p<0.01)：经TNF-a预刺激后再用同浓度APS IgG干预细胞,SELE、 MCP-1、IL-6和IL-8表达量与仅用APS IgG干预组比较明显增高,差异有统计学意义(p<0.01),不同浓度APS IgG组与正常对照组四组之间两两比较,差异均有统计学意义(p<0.01)；
抗-TLR2+APS IgG组及抗-TLR2+抗-TLR4组内皮细胞SELE、 MCP-1、IL-6和IL-8表达量,较APS IgG组明显降低,差异有统计学意义(p<0.01)；抗-TLR4+APS IgG组内皮细胞SELE. MCP-1、 IL-6和IL-8表达量,与APS IgG组比较无明显改变,差异无统计学意义(p>0.05)。
结论：
(1)TNF-a干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、 IL-8、MCP-1的作用增强。
(2)抗磷脂抗体通过TLR2信号传导通路刺激内皮细胞使其E-选择素、IL-6、IL-8、MCP-1分泌增加。
第三章卡介菌多糖核酸对抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的影响
目的：
探讨卡介菌多糖核酸(BCG-PSN)干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的情况。
方法：
用APS患者血清提取的IgG处理内皮细胞,APS IgG处理前预先加入不同浓度BCG-PSN(0、25、50和100μg/ml),采用实时荧光定量PCR及流式细胞学技术,检测细胞E-选择素表达,采用ELISA测定细胞分泌MCP-1、IL-6和IL-8的表达。
结果：
BCG-PSN干预下APS IgG所诱导的内皮细胞SELE.MCP-1、IL-6和IL-8表达明显降低,APS IgG组及不同浓度BCG-PSN组之间两两比较,差异均有统计学意义(p<0.01)。
结论：
卡介菌多糖核酸干预下抗磷脂抗体刺激内皮细胞分泌E-选择素、IL-6、IL-8、MCP-1的作用减弱,提示它可以用于APS的治疗。
Antiphospholipid syndrome (APS) is a systemic autoimmune disease, the presence of antiphospholipid antibody (aPL) in the serum and generalized prothrombotic state are the two major characteristics, and this serological characteristics are closely related to embolism and pathological pregnancy. The pathogenesis of APS is still unclear, prothromboticstate is one of the important factors, and the important factor required for the formation of prothromboticstate is endothelial cells'damage and activation. About the relation between the concentration of aPL, infection and the incidence and prognosis of APS, some foreign scholars believe that the higher the concentration, the worse the prognosis, infection can make APS worse. What makes this phenomenon? Is the activation of endothelial cell involved in it? No such research has been seen in China.
One of the major receptors for aPL is β2-glycoprotein I (β2GPI). aPL/β2GPI complex further binds to annexin A2, then combines with phospholipids on the cell membrane, however, annexin A2does not have the transmembrane structure, cell signal cannot be conducted. Many researches have been focused on toll-like receptor (TLR) signaling pathway and found that TLR2mediated the signal transduction, disagreement was existed about the role of TLR4, no such research in China.
After activation, the synthesis and secretion of adhesion molecule such as E-selectin (SELE) significantly increased, a number of inflammatory cytokines such as interleukin-1β(IL-1β), interleukin-6(IL-6),interleukin-8(IL-8), tumor necrosis factor-a (TNF-a), monocyte chemoattractant protein-1(MCP-1) also increased significantly, resulting in a proinflammatory and procoagulant state. Among them, E-selectin、 IL-6、IL-8、MCP-1are the most sensitive and frequently used factors in monitoring the endothelial cells'activation extent. The consistent change of SELE mRNA and pretein levels means the correctness of the experimental results. Limited by the experimental techniques and conditions, the aPL used in our research is the purified IgG from APS patients, the purified IgG from normal person was used as normal control to exclude the possible effects of the normal types of IgG.
The paper is divided into three parts:the first part was to investigate the effects of various titers of aPL on endothelial cells. Culturing human umbilical vein endothelial cells (HUVECs) in vitro, stimulating them with purified IgG proteins from APS or normal non-pregnant women. Endothelial cell secretion function was assessed by measuring mRNA and protein levels of E-selectin by the means of real-time fluorescent quantitative-polymerase chain reaction (RT-PCR) and flow cytometry (FACS), the protein levels of MCP-1, IL-6and IL-8were measured by mean of enzyme-linked immunosorbent assay (ELISA), TLR2and TLR4 were measured by Western blot. The second part was to study the effect of TNF-α and the role of TLR2and TLR4in activation of the endothelial cells by aPL. By blocking TLR2or (and) TLR4signal transduction way, we study the role of TLR2/4directly. The third part was about investigating the effects of BCG polysaccharides nucleic acid (BCG-PSN) in activation of endothelial cells by aPL, to explore whether BCG-PSN can be used in APS.
Chapter1
Secretion of E-selectin, IL-6, IL-8and MCP-1by endothelial cell stimulated by various titers of antiphospholipid antibody
Objective:
To study the expression of E-selectin, IL-6, IL-8, MCP-1on endothelial cell when stimulated by various titers of aPLs.
Methods:
HUVECs were cultured in vitro, and stimulated with aPLs from APS (5%,10%,20%) or normal non-pregnant women. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA, Western blot analysis was used to measure the protein levels of TLR2and TLR4.
Results:
Stimulated by aPL showed a significant increase in SELE, IL-6, IL-8, MCP-1expression, comparing every two groups of blank, normal control or aPL (5%,10%,20%) groups, p<0.01.
There are no significant difference on TLR2expression between the groups of blank, normal and5%aPL(p>0.05), TLR2expression in10%and20%aPL groups were significantly increased compared with the blank and normal control groups or with each other (p<0.05). aPL has no effect on the expression of TLR4(p>0.05)
Conclusions:
Expression of E-selectin, IL-6, IL-8and MCP-1on endothelial cell increased when stimulated by aPL, the higher the antibody concentration, the higher the expression.
Chapter2
The role of TNF-a, TLR2and TLR4in activation of endothelial cell by antiphospholipid antibodiy
Objective:
To investigate the role of TNF-a, TLR2/4in secretion function of endothelial cell when stimulated by antiphospholipid antibodiy.
Methods:
(1) HUVECs were cultured in vitro, part of them were stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, collecting some TNF-pretreated and non-pretreated cells, using Western blot analysis to measure the protein levels of TLR2and TLR4. The rest cells were stimulated with LTA or aPLs from APS women. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA;(2) HUVECs were cultured in vitro and stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, then treated with aPL, Anti-TLR2antibodies or/and anti-TLR4antibodies were used before adding aPL to block TLR2or/and TLR4signal conduct pathways. Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8 were measured by mean of ELISA.
Results:
After pre-stimulation by TNF-a, the TLR2expression on HUVEC was significantly increased compared with the non-pretreated group (p<0.01), the TLR4expression had no change (p>0.05). stimulated by LTA, the specific agonist of TLR2, the expression of SELE, IL-6, IL-8, MCP-1were significantly increased in TNF-apretreated group compared with the non-pretreated group (p<0.01). Under the same concentration of aPL, the expression of SELE, IL-6, IL-8, MCP-1in TNF-pretreated group were significantly higher than non-pretreated group (p<0.01).
Blocking TLR2signal conduct pathways significantly attenuated the expression of SELE, IL-6, IL-8, MCP-1expression on HUVEC stimulated by aPL (p<0.01). blocking TLR4did not have significant effect on the expression of SELE, IL-6, IL-8, MCP-1stimulated by aPL HUVEC (p>0.05).
Conclusions:
(1) TNF-apre-treated endothelial cell secretes more SELE, IL-6, IL-8, MCP-1than non-pre-treated cell when stimulated by aPL.
(2) Antiphospholipid antibodies activate endothelial cell via TLR2signal transduction pathways.
Chapter3
The impact of BCG-polysaccharides nucleic acid on E-selectin, IL-6, IL-8and MCP-1expression on endothelial cell stimulated by antiphospholipid antibody
Objective:
To investigate the impact of BCG-polysaccharides nucleic acid (BCG-PSN) on secretion function of endothelial cell stimulated by antiphospholipid antibody.
Methods:
HUVECs were cultured in vitro, and stimulated with100ng/ml TNF-a for24hours followed by an8h wash-out, then treated with20%of APS aPLs, APS aPLs treated groups were also treated with different concentrations of BCG-PSN (0,25,50and100μg/ml). Endothelial cell activation was assessed by measuring mRNA and protein levels of E-selectin by the means of RT-PCR and FACS, the protein levels of MCP-1, IL-6and IL-8were measured by mean of ELISA.
Results:
APS IgG induced endothelial cells' SELE, IL-6, IL-8, MCP-1expression increasing, while the intervention of BCG-PSN attenuated APS IgG-induced SELE, IL-6, IL-8, MCP-1expression, compared any two of BCG-PSN groups (0,25,50and100μg/ml), the differences were statistically significant (p<0.01).
Conclusion:
Antiphospholipid antibody induced secretion of E-selection, IL-6, IL-8, MCP-1on endothelial cell decreased when interfered by BCG-polysaccharides nucleic acid, suggesting that it may be useful for the treatment of APS.
引文
[1]Salmon J E, Girardi G. Antiphospholipid antibodies and pregnancy loss:a disorder of inflammation[J]. J Reprod Immunol,2008,77(1):51-56.
[2]Hughes G R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant[J]. Br Med J (Clin Res Ed),1983,287(6399):1088-1089.
[3]Wilson W A, Gharavi A E, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop.[J]. Arthritis Rheum,1999,42(7):1309-1311.
[4]George J, Blank M, Levy Y, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome[J]. Circulation,1998,97(9):900-906.
[5]Pierangeli S S, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models[J]. Thromb Haemost,2000,84(3):388-395.
[6]Blank M, Shoenfeld Y, Cabilly S, et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides[J]. Proc Natl Acad Sci U S A,1999,96(9):5164-5168.
[7]Pierangeli S S, Liu S W, Anderson G, et al. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies[J]. Circulation,1996,94(7):1746-1751.
[8]Miyakis S, Lockshin M D, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost,2006,4(2):295-306.
[9]Tripodi A, de Groot P G, Pengo V. Antiphospholipid syndrome:laboratory detection, mechanisms of action and treatment[J]. J Intern Med,2011,270(2):110-122.
[10]Mehdi A A, Uthman I, Khamashta M. Antiphospholipid syndrome:pathogenesis and a window of treatment opportunities in the future[J]. Eur J Clin Invest,2010,40(5):451-464.
[11]Ornoy A, Yacobi S, Matalon S T, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture[J]. Lupus,2003,12(7):573-578.
[12]Ernest J M, Marshburn P B, Kutteh W H. Obstetric antiphospholipid syndrome: an update on pathophysiology and management J]. Semin Reprod Med,2011,29(6):522-539.
[13]黄健,朱付凡,丁依玲,等.106例妊娠血小板减少临床分析[J].湖南医科大学学报,2003,28(5)：544-546.
[14]杨励勤,朱付凡.抗磷脂综合征和前置胎盘的相关性研究[J].实用妇产科杂志,2007,23(4)：223-225.
[15]谭凌,尹爱武,朱付凡.抗心磷脂抗体阳性与流产关系的临床研究[J].中国计划生育学杂志,2004(12).
[16]朱付凡,孙文霞,黄健.抗心磷脂抗体与各类流产的关系[J].湖南医科大学学报,2003,28(1)：70-72.
[17]孙文霞,朱付凡.抗心磷脂抗体在病理妊娠中的意义[J].长治医学院学报,2001,15(3)：166-168.
[18]Mulla M J, Brosens J J, Chamley L W, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway[J]. Am J Reprod Immunol,2009,62(2):96-111.
[19]Sene D, Piette J C, Cacoub P. [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections][J]. Rev Med Interne,2009,30(2):135-141.
[20]Uthman I W, Gharavi A E. Viral infections and antiphospholipid antibodies[J]. Semin Arthritis Rheum,2002,31(4):256-263.
[21]Willis R, Harris E N, Pierangeli S S. Pathogenesis of the Antiphospholipid Syndrome[J]. Semin Thromb Hemost,2012.
[22]Blank M, Asherson R A, Cervera R, et al. Antiphospholipid syndrome infectious origin[J]. J Clin Immunol,2004,24(1):12-23.
[23]Shoenfeld Y, Blank M, Cervera R, et al. Infectious origin of the antiphospholipid syndrome[J]. Ann Rheum Dis,2006,65(1):2-6.
[24]Rojas-Rodriguez J, Garcia-Carrasco M, Ramos-Casals M, et al. Catastrophic antiphospholipid syndrome:clinical description and triggering factors in 8 patients [J]. J Rheumatol,2000,27(1):238-240.
[25]Undas A, Swadzba J, Undas R, et al. [Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome][J]. Pol Arch Med Wewn,1998,100(6):556-560.
[26]Fu B D, Yamawaki H, Okada M, et al. Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells[J]. J Vet Med Sci,2009,71(9):1201-1207.
[27]Chen H W, Lin A H, Chu H C, et al. Inhibition of TNF-alpha-Induced Inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway[J]. J Nat Prod,2011,74(11):2408-2413.
[28]Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells[J]. Atherosclerosis,2012,221(2):375-382.
[29]Liu X, Pan L, Wang X, et al. Leonurine protects against tumor necrosis factor-alpha-mediated inflammation in human umbilical vein endothelial cells[J]. Atherosclerosis,2012,222(1):34-42.
[30]Lee Y R, Kim K M, Jeon B H, et al. The n-butanol fraction of Naematoloma sublateritium suppresses the inflammatory response through downregulation of NF-kappaB in human endothelial cells[J]. Int J Mol Med,2012,29(5):801-808.
[31]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies[J]. Blood,2003,101(9):3495-3500.
[32]Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies[J]. Arthritis Rheum,2005,52(5):1545-1554.
[33]Vega-Ostertag M E, Ferrara D E, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation[J]. J Thromb Haemost,2007,5(9):1828-1834.
[34]Ma K, Simantov R, Zhang J C, et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II[J]. J Biol Chem,2000,275(20):15541-15548.
[35]Navarro M, Cervera R, Teixido M, et al. Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome:prevalence and isotype distribution[J]. Br J Rheumatol,1996,35(6):523-528.
[36]Cockrell E, Espinola R G, Mccrae K R. Annexin A2:biology and relevance to the antiphospholipid syndrome[J]. Lupus,2008,17(10):943-951.
[37]Satta N, Kruithof E K, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies[J]. Blood,2011,117(20):5523-5531.
[38]Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of beta2-glycoprotein I cross-react with TLR4 inducing a pro-inflammatory phenotype in endothelial cells and monocytes[J]. Blood,2012.
[39]Pierangeli S S, Vega-Ostertag-M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies[J]. Thromb Res,2004,114(5-6):467-476.
[40]Mak A, Cheung M W, Cheak A A, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies:a meta-analysis of randomized controlled trials and meta-regression[J]. Rheumatology (Oxford),2010,49(2):281-288.
[41]Ferrara D E, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells [J]. J Thromb Haemost,2004,2(9):1558-1563.
[42]李桑琳,朱付凡.产科抗磷脂综合征患者血清对脐静脉内皮细胞活化的研究[J].中国优生与遗传杂志,2008(7).
[43]Cohen D, Berger S P, Steup-Beekman G M, et al. Diagnosis and management of the antiphospholipid syndrome[J]. BMJ,2010,340:c2541.
[44]Yetman D L, Kutteh W H. Antiphospholipid antibody panels and recurrent pregnancy loss:prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies [J]. Fertil Steril,1996,66(4):540-546.
[45]Matzner W, Chong P, Xu G, et al. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions [J]. J Reprod Med,1994,39(1):27-30.
[46]Skrzypczak J, Rajewski M, Wirstlein P, et al. [Frequency of antiphospholipid syndrome in women with pregnancy loss in multicenter study in Poland][J]. Ginekol Pol,2011,82(10):749-754.
[47]Giasuddin A S, Mazhar I, Haq A M. Prevalence of anticardiolipin antibody in Bangladeshi patients with recurrent pregnancy loss[J]. Bangladesh Med Res Counc Bull,2010,36(1):10-13.
[48]Simchen M J, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome[J]. Acta Obstet Gynecol Scand,2011,90(12):1428-1433.
[49]Silver R M, Porter T F, van Leeuween I, et al. Anticardiolipin antibodies:clinical consequences of "low titers"[J]. Obstet Gynecol,1996,87(4):494-500.
[50]Levine S R, Salowich-Palm L, Sawaya K L, et al. IgG anticardiolipin antibody titer> 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study[J]. Stroke,1997,28(9):1660-1665.
[51]Erkan D, Barbhaiya M, George D, et al. Moderate versus high-titer persistently anticardiolipin antibody positive patients:are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?[J].Lupus,2010,19(5):613-619.
[52]Christenson L K, Stouffer R L. Isolation and culture of micro vascular endothelial cells from the primate corpus luteum[J]. Biol Reprod,1996,55(6):1397-1404.
[53]姜开余.白细胞介素6的作用与临床应用前景[J].临床肿瘤学杂志,1997(1)：71-73.
[54]Oldstone M B. Molecular mimicry and immune-mediated diseases[J]. FASEB J,1998,12(13):1255-1265.
[55]Karlsen A E, Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity[J]. Semin Immunol,1998,10(1):25-34.
[56]Albert L J, Inman R D. Molecular mimicry and autoimmunity[J]. N Engl J Med,1999,341 (27):2068-2074.
[57]Regner M, Lambert P H. Autoimmunity through infection or immunization?[J]. Nat Immunol,2001,2(3):185-188.
[58]Wucherpfennig K W. Structural basis of molecular mimicry[J]. J Autoimmun,2001,16(3):293-302.
[59]Rauch J, Dieude M, Subang R, et al. The dual role of innate immunity in the antiphospholipid syndrome[J]. Lupus,2010,19(4):347-353.
[60]Pierangeli S S, Gharavi A E, Harris E N. Experimental thrombosis and antiphospholipid antibodies:new insights[J]. J Autoimmun,2000,15(2):241-247.
[61]Takeda K, Kaisho T, Akira S. Toll-like receptors[J]. Annu Rev Immunol,2003,21:335-376.
[62]Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway [J]. Science,2003,301(5633):640-643.
[63]Raschi E, Borghi M O, Grossi C, et al. Toll-like receptors:another player in the pathogenesis of the anti-phospholipid syndrome[J]. Lupus,2008,17(10):937-942.
[64]Marshak-Rothstein A, Ohashi P S. Intricate connections between innate and adaptive autoimmunity [J]. Curr Opin Immunol,2007,19(6):603-605.
[65]Pasare C, Medzhitov R. Toll-like receptors:linking innate and adaptive immunity[J]. Adv Exp Med Biol,2005,560:11-18.
[66]Marshak-Rothstein A, Rifkin I R. Immunologically active autoantigens:the role of toll-like receptors in the development of chronic inflammatory disease[J]. Annu Rev Immunol,2007,25:419-441.
[67]Hurst J, von Landenberg P. Toll-like receptors and autoimmunity [J]. Autoimmun Rev,2008,7(3):204-208.
[68]Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer[J]. Int Immunopharmacol,2007,7(10):1271-1285.
[69]Krutzik S R, Ochoa M T, Sieling P A, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy[J]. Nat Med,2003,9(5):525-532.
[70]Triantafilou M, Gamper F G, Haston R M, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting[J]. J Biol Chem,2006,281(41):31002-31011.
[71]Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts [J]. Arthritis Rheum,2007,56(8):2687-2697.
[72]Meroni P L, Raschi E, Testoni C, et al. Innate immunity in the antiphospholipid syndrome:role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies[J]. Autoimmun Rev,2004,3(7-8):510-515.
[73]Lopez-Pedrera C, Buendia P, Cuadrado M J, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway [J]. Arthritis Rheum,2006,54(1):301-311.
[74]Pierangeli S S, Vega-Ostertag M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies[J]. Thromb Res,2004,114(5-6):467-476.
[75]Doring Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8[J]. Immunobiology,2010,215(3):230-241.
[76]Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-lbeta and caspase-1 in monocytes and dendritic cells[J]. Immunobiology,2009,214(8):683-691.
[77]Satta N, Dunoyer-Geindre S, Reber G, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies[J]. Blood,2007,109(4):1507-1514.
[78]宁云山,姜德建,刘珊珊.卡介苗及卡介菌多糖核酸提取物的免疫调节作用及临床应用[J].中国生物制品学杂志,2008(1)：74-77.
[79]刘光辉,祝戎飞.卡介菌多糖核酸对NF-κB的活化调控[J].中国医院药学杂 志,2005(4)：308-310.
[80]李永喜,陈兴平,邓云华,等.卡介菌多糖核酸对正常小鼠T淋巴细胞亚群的影响[J].青岛大学医学院学报,2004(4).
[81]刘光辉,祝戎飞.卡介菌多糖核酸对NF-κB的活化调控[J].中国医院药学杂志,2005(4)：308-310.
[82]Satta N, Kruithof E K, Reber G, et al. Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides[J]. Mol Immunol,2008,46(1):145-157.
[1]Hughes G R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.[J]. Br Med J (Clin Res Ed),1983,287(6399):1088-1089.
[2]Wilson W A, Gharavi A E, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop.[J]. Arthritis Rheum,1999,42(7):1309-1311.
[3]Miyakis S, Lockshin M D, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).[J]. J Thromb Haemost,2006,4(2):295-306.
[4]Sinico R A, Di Toma L, Sabadini E, et al. Catastrophic antiphospholipid syndrome:report of 4 cases.[J]. J Nephrol,2007,20(6):739-744.
[5]Cervera R, Font J, Gomez-Puerta J A, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.[J]. Ann Rheum Dis,2005,64(8):1205-1209.
[6]Asherson R A, Cervera R, de Groot P G, et al. Catastrophic antiphospholipid syndrome:international consensus statement on classification criteria and treatment guidelines.[J]. Lupus,2003,12(7):530-534.
[7]Cervera R, Piette J C, Font J, et al. Antiphospholipid syndrome:clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.[J]. Arthritis Rheum,2002,46(4):1019-1027.
[8]Tektonidou M G, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome:association with clinical, laboratory, and brain magnetic resonance imaging findings. [J]. Arch Intern Med,2006,166(20):2278-2284.
[9]Cuadrado M J, Khamashta M A, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.[J]. Medicine (Baltimore),2000,79(1):57-68.
[10]Sanna G, Bertolaccini M L, Cuadrado M J, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome.[J]. Rheumatology (Oxford),2003,42(2):200-213.
[11]Branch D W, Khamashta M A. Antiphospholipid syndrome:obstetric diagnosis, management, and controversies.[J]. Obstet Gynecol,2003,101(6):1333-1344.
[12]Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.[J]. BMJ,2005,330(7491):565.
[13]Ruiz-Irastorza G, Khamashta M A. Antiphospholipid syndrome in pregnancy.[J]. Rheum Dis Clin North Am,2007,33(2):287-297.
[14]Opatrny L, David M, Kahn S R, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease:a metaanalysis.[J]. J Rheumatol,2006,33(11):2214-2221.
[15]Nodler J, Moolamalla S R, Ledger E M, et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes:analysis of a population-based hospital dataset.[J]. BMC Pregnancy Childbirth,2009,9:11.
[16]Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome:recommendations for treatment. Committee consensus report.[J]. Lupus,2003,12(7):518-523.
[17]Tektonidou M G, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies:prevalence, clinical associations, and long-term outcome.[J]. Arthritis Rheum,2004,50(8):2569-2579.
[18]Amigo M C, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome.[J]. J Rheumatol,1992,19(8):1181-1185.
[19]Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome.[J]. Blood Rev,2008,22(4):187-194.
[20]Blume J E, Miller C C. Antiphospholipid syndrome:a review and update for the dermatologist.[J]. Cutis,2006,78(6):409-415.
[21]Pierangeli S S, Chen P P, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome:pathogenic mechanisms. [J]. Semin Thromb Hemost,2008,34(3):236-250.
[22]Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.[J]. Blood,2003,101(1):157-162.
[23]Haupt H, Schwick H G, Storiko K. [On a hereditary beta-2-glycoprotein I deficiency]. [J]. Humangenetik,1968,5(4):291-293.
[24]Makatsariya A, Asherson R A, Bitsadze V, et al. Catastrophic antiphospholipid (Asherson's) syndrome and genetic thrombophilic disorders in obstetrics. [J]. Autoimmun Rev,2006,6(2):89-93.
[25]Agar C, van Os G M, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations:implications for our understanding of the antiphospholipid syndrome.[J]. Blood,2010,116(8):1336-1343.
[26]Matsuura E, Igarashi Y, Yasuda T, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.[J]. J Exp Med,1994,179(2):457-462.
[27]de Laat B, Derksen R H, Urbanus R T, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.[J]. Blood,2005,105(4):1540-1545.
[28]Matsuura E, Inagaki J, Kasahara H, et al. Proteolytic cleavage of beta(2)-glycoprotein I:reduction of antigenicity and the structural relationship.[J]. Int Immunol,2000,12(8):1183-1192.
[29]Oosting J D, Derksen R H, Bobbink I W, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S:an explanation for their pathogenic mechanism?[J]. Blood,1993,81(10):2618-2625.
[30]Hurtado V, Montes R, Gris J C, et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death.[J]. Blood,2004,104(5):1369-1374.
[31]Oosting J D, Preissner K T, Derksen R H, et al. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro.[J]. Br J Haematol,1993,85(4):761-768.
[32]Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. [J]. Blood,1998,91 (6):1999-2004.
[33]Marciniak E, Romond E H. Impaired catalytic function of activated protein C:a new in vitro manifestation of lupus anticoagulant. [J]. Blood,1989,74(7):2426-2432.
[34]Boyanovski B, Russeva M, Dobreva G, et al. Protein C Activity in Patients with Antiphospholipid Syndrome.[J]. J Clin Rheumatol,2000,6(5):239-243.
[35]Ruiz-Arguelles G J, Ruiz-Arguelles A, Deleze M, et al. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin.[J]. J Rheumatol,1989,16(3):381-383.
[36]Angles-Cano E, Guillin M C. Antiphospholipid antibodies and the coagulation cascade.[J]. Rheum Dis Clin North Am,2001,27(3):573-586.
[37]Roubey R A. Autoantibodies to phospholipid-binding plasma proteins:a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies.[J]. Blood,1994,84(9):2854-2867.
[38]Macko R F, Ameriso S F, Gruber A, et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. [J]. Stroke,1996,27(11):2005-2011.
[39]Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.[J]. Thromb Haemost,2002,88(5):716-722.
[40]Tomas J F, Alberca I, Tabernero M D, et al. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.[J]. J Rheumatol,1998,25(1):57-62.
[41]Atsumi T, Khamashta M A, Ames P R, et al. Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system.[J]. Lupus,1997,6(4):358-364.
[42]Gris J C, Toulon P, Brun S, et al. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection.[J]. Thromb Haemost,1996,76(1):38-45.
[43]Merrill J T, Zhang H W, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies:beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein.[J]. Thromb Haemost,1999,81(5):748-757.
[44]Ames P R, Tommasino C, Iannaccone L, et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. [J]. Thromb Haemost,1996,76(2):190-194.
[45]Jurado M, Paramo J A, Gutierrez-Pimentel M, et al. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.[J]. Thromb Haemost,1992,68(5):516-520.
[46]Ieko M, Sawada K I, Koike T, et al. The putative mechanism of thrombosis in antiphospholipid syndrome:impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. [J]. Semin Thromb Hemost,1999,25(5):503-507.
[47]Ieko M, Ichikawa K, Atsumi T, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis.[J]. Semin Thromb Hemost,2000,26(1):85-90.
[48]Varela F, Andersson A, Dietrich G, et al. Population dynamics of natural antibodies in normal and autoimmune individuals.[J]. Proc Natl Acad Sci U S A,1991,88(13):5917-5921.
[49]Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome.[J]. Br J Haematol,2000,108(4):871-875.
[50]Takeuchi R, Atsumi T, Ieko M, et al. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies:possible mechanism for thrombosis in patients with antiphospholipid syndrome. [J]. Br J Haematol,2002,119(3):781-788.
[51]Takeya H, Mori T, Gabazza E C, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.[J]. J Clin Invest,1997,99(9):2260-2268.
[52]Rus H G, Niculescu F I, Shin M L. Role of the C5b-9 complement complex in cell cycle and apoptosis.[J]. Immunol Rev,2001,180:49-55.
[53]Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.[J]. J Clin Invest,2003,112(11):1644-1654.
[54]Girardi G, Redecha P, Salmon J E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.[J]. Nat Med,2004,10(11):1222-1226.
[55]Holers V M, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.[J]. J Exp Med,2002,195(2):211-220.
[56]Ikematsu W, Luan F L, La Rosa L, et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice.[J]. Arthritis Rheum,1998,41(6):1026-1039.
[57]Thurman J M, Kraus D M, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.[J], Mol Immunol,2005,42(1):87-97.
[58]Pierangeli S S, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.[J]. Arthritis Rheum,2005,52(7):2120-2124.
[59]Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.[J]. J Immunol,2006,177(7):4794-4802.
[60]Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome.[J]. Ann Rheum Dis,2009,68(6):1030-1035.
[61]Davis W D, Brey R L. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.[J]. Clin Exp Rheumatol,1992,10(5):455-460.
[62]Nachman R L, Silverstein R. Hypercoagulable states.[J]. Ann Intern Med,1993,119(8):819-827.
[63]Romay-Penabad Z, Montiel-Manzano M G, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.[J]. Blood,2009,114(14):3074-3083.
[64]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. [J]. Blood,2003,101(9):3495-3500.
[65]Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies.[J]. Arthritis Rheum,2005,52(5):1545-1554.
[66]Vega-Ostertag M E, Ferrara D E, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. [J]. J Thromb Haemost,2007,5(9):1828-1834.
[67]Alard J E, Gaillard F, Daridon C, et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I.[J]. J Immunol,2010,185(3):1550-1557.
[68]Satta N, Kruithof E K, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies.[J]. Blood,2011,117(20):5523-5531.
[69]Simantov R, Lasala J M, Lo S K, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. [J]. J Clin Invest,1995,96(5):2211-2219.
[70]Gharavi A E, Pierangeli S S, Colden-Stanfield M, et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro.[J]. J Immunol,1999,163(5):2922-2927.
[71]Pierangeli S S, Espinola R G, Liu X, et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.[J]. Circ Res,2001,88(2):245-250.
[72]Atsumi T, Khamashta M A, Haworth R S, et al. Arterial disease and thrombosis in the antiphospholipid syndrome:a pathogenic role for endothelin 1.[J]. Arthritis Rheum,1998,41(5):800-807.
[73]Blann A D, Miller J P, Mccollum C N. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia.[J]. Atherosclerosis,1997,132(2):151-156.
[74]Lindsey N J, Dawson R A, Henderson F I, et al. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome.[J]. Br J Rheumatol,1993,32(2):123-126.
[75]Levy Y, Shenkman B, Tamarin I, et al. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. [J]. Arthritis Rheum,2005,52(12):4011-4017.
[76]van Baal W M, Kenemans P, Emeis J J, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. [J]. Fertil Steril,1999,71(4):663-670.
[77]Sadler J E. Thrombomodulin structure and function. [J]. Thromb Haemost,1997,78(1):392-395.
[78]Haruta K, Kobayashi S, Hirose S, et al. Monoclonal anti-cardiolipin antibodies from New Zealand Black x New Zealand White F1 mice react to thrombomodulin.[J]. J Immunol,1998,160(1):253-258.
[79]Ichikawa K, Suzuki T, Hashimoto Y, et al. Monoclonal autoantibodies to cardiolipin derived from SLE mice.[J]. Lupus,1992,1(4):239-247.
[80]Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies.[J]. Int Immunol,2004,16(11):1633-1641.
[81]Lopez-Pedrera C, Buendia P, Cuadrado M J, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.[J]. Arthritis Rheum,2006,54(1):301-311.
[82]Meroni P L, Raschi E, Testoni C, et al. Innate immunity in the antiphospholipid syndrome:role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies.[J]. Autoimmun Rev,2004,3(7-8):510-515.
[83]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. [J]. Blood,2003,101(9):3495-3500.
[84]Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. [J]. Arthritis Rheum,2007,56(8):2687-2697.
[85]Doling Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8.[J]. Immunobiology,2010,215(3):230-241.
[86]Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-lbeta and caspase-1 in monocytes and dendritic cells.[J]. Immunobiology,2009,214(8):683-691.
[87]Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. [J]. J Immunol,1994,153(3):1328-1332.
[88]Cuadrado M J, Lopez-Pedrera C, Khamashta M A, et al. Thrombosis in primary antiphospholipid syndrome:a pivotal role for monocyte tissue factor expression. [J]. Arthritis Rheum,1997,40(5):834-841.
[89]Segal J, Kickler T, Petri M. Tissue factor activity in patients with systemic lupus erythematosus:association with disease activity. [J]. J Rheumatol,2000,27(12):2827-2832.
[90]Campbell A L, Pierangeli S S, Wellhausen S, et al. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. [J]. Thromb Haemost,1995,73(3):529-534.
[91]Arvieux J, Roussel B, Pouzol P, et al. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I.[J]. Thromb Haemost,1993,70(2):336-341.
[92]Khamashta M A, Harris E N, Gharavi A E, et al. Immune mediated mechanism for thrombosis:antiphospholipid antibody binding to platelet membranes.[J]. Ann Rheum Dis,1988,47(10):849-854.
[93]de Groot P G, van Lummel M, Pennings M, et al. Beta2-glycoprotein I and LDL-receptor family members.[J].Thromb Res,2004,114(5-6):455-459.
[94]Pierangeli S S, Vega-Ostertag M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies.[J]. Thromb Res,2004,114(5-6):467-476.
[95]Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.[J]. Arthritis Rheum,2006,54(8):2558-2567.
[96]Reverter J C, Tassies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.[J]. Arthritis Rheum,1998,41(8):1420-1427.
[97]Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.[J]. N Engl J Med,2002,346(10):752-763.
[98]Robbins D L, Leung S, Miller-Blair D J, et al. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome.[J]. J Rheumatol,1998,25(1):51-56.
[99]Redecha P, Tilley R, Tencati M, et al. Tissue factor:a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury.[J], Blood,2007,110(7):2423-2431.
[100]Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.[J]. J Clin Invest,2003,112(11):1644-1654.
[101]Di Simone N, Marana R, Castellani R, et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation.[J]. Arthritis Rheum,2010,62(5):1504-1512.
[102]Mulla M J, Brosens J J, Chamley L W, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.[J]. Am J Reprod Immunol,2009,62(2):96-111.
[103]Yu P, Passam F H, Yu D M, et al. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. [J]. J Thromb Haemost,2008,6(7):1215-1223.
[104]Merten M,Motamedy S, Ramamurthy S, et al. Sulfatides:targets for anti-phospholipid antibodies.[J]. Circulation,2003,108(17):2082-2087.
[105]Delgado A J, Mason L J, Ames P R, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model.[J]. Rheumatology (Oxford),2005,44(10):1238-1244.
[106]Rao L V, Hoang A D, Rapaport S I. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid.[J]. Blood,1996,88(11):4173-4182.
[107]Dombroski D, Balasubramanian K, Schroit A J. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice.[J]. J Autoimmun,2000,14(3):221-229.
[108]Salemink I, Blezer R, Willems G M, et al. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor.[J]. Thromb Haemost,2000,84(4):653-656.
[109]Brachvogel B, Dikschas J, Moch H, et al. Annexin A5 is not essential for skeletal development.[J]. Mol Cell Biol,2003,23(8):2907-2913.
[110]Kearon C, Kahn S R, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).[J]. Chest,2008,133(6 Suppl):454S-545S.
[111]Tripodi A, de Groot P G, Pengo V. Antiphospholipid syndrome:laboratory detection, mechanisms of action and treatment. [J]. J Intern Med,2011,270(2):110-122.
[112]Prandoni P, Prins M H, Lensing A W, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis:a randomized trial.[J]. Ann Intern Med,2009,150(9):577-585.
[113]Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy.[J]. N Engl J Med,2006,355(17):1780-1789.
[114]Cosmi B, Legnani C, Tosetto A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism:the extended follow-up of the PROLONG study.[J]. J Thromb Thrombolysis,2009,28(4):381-388.
[115]Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).[J]. J Thromb Haemost,2005,3(5):848-853.
[116]Crowther M A, Ginsberg J S, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.[J]. N Engl J Med,2003,349(12):1133-1138.
[117]Khamashta M A, Cuadrado M J, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. [J]. N Engl J Med,1995,332(15):993-997.
[118]Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS).[J].Neurology,1997,48(l):91-94.
[119]Lim W, Crowther M A, Eikelboom J W. Management of antiphospholipid antibody syndrome:a systematic review.[J]. JAMA,2006,295(9):1050-1057.
[120]Ruiz-Irastorza G, Hunt B J, Khamashta M A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.[J]. Arthritis Rheum,2007,57(8):1487-1495.
[121]Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome.[J]. Lancet,2010,376(9751):1498-1509.
[122]Mak A, Cheung M W, Cheak A A, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies:a meta-analysis of randomized controlled trials and meta-regression.[J]. Rheumatology (Oxford),2010,49(2):281-288.
[123]Ziakas P D, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss:a systematic review and meta-analysis.[J]. Obstet Gynecol,2010,115(6):1256-1262.
[124]Noble L S, Kutteh W H, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss:prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.[J]. Fertil Steril,2005,83(3):684-690.
[125]Bates S M, Greer I A, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).[J]. Chest,2008,133(6 Suppl):844S-886S.
[126]Carmona F, Font J, Azulay M, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies:a multivariate analysis.[J]. Am J Reprod Immunol,2001,46(4):274-279.
[127]Silver R K, Macgregor S N, Sholl J S, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. [J]. Am J Obstet Gynecol,1993,169(6):1411-1417.
[128]Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome.[J]. Rheumatology (Oxford),2000,39(4):421-426.
[129]Branch D W, Peaceman A M, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.[J]. Am J Obstet Gynecol,2000,182(1 Pt 1):122-127.
[130]Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies:a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin.[J]. Am J Reprod Immunol,2001,45(3):174-179.
[131]Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.[J]. Arthritis Rheum,2003,48(3):728-731.
[132]Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.[J]. Cochrane Database Syst Rev,2005(2):D2859.
[133]Huong D L, Wechsler B, Bletry O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome.[J]. J Rheumatol,2001,28(9):2025-2030.
[134]Antiplatelet agents for prevention of pre-eclampsia and its consequences:a systematic review and individual patient data meta-analysis.[J]. BMC Pregnancy Childbirth,2005,5(1):7.
[135]Ruiz-Irastorza G, Khamashta M A. Lupus and pregnancy:ten questions and some answers.[J]. Lupus,2008,17(5):416-420.
[136]Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome.[J]. Lancet,2010,376(9751):1498-1509.
[137]Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. [J]. Arthritis Res Ther,2006,8(3):209.
[138]Ferrara D E, Liu X, Espinola R G, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.[J]. Arthritis Rheum,2003,48(11):3272-3279.
[139]Meroni P L, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.[J]. Arthritis Rheum,2001,44(12):2870-2878.
[140]Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome?[J]. Ann N Y Acad Sci,2009,1173:736-745.
[141]Pierangeli S S, Vega-Ostertag M E, Gonzalez E B. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. [J]. Expert Rev Mol Med,2007,9(30):1-15.
[142]Rand J H, Wu X X, Quinn A S, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.[J]. Blood,2008,112(5):1687-1695.
[143]-Espinola R G, Pierangeli S S, Gharavi A E, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.[J]. Thromb Haemost,2002,87(3):518-522.
[144]Ehrnthaller C, Ignatius A, Gebhard F, et al. New insights of an old defense system:structure, function, and clinical relevance of the complement system.[J]. Mol Med,2011,17(3-4):317-329.
[145]Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab.[J]. Br J Haematol,2010,149(3):446-450.
[146]Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. [J]. Arthritis Rheum,2008,58(9):2824-2834.
[147]Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.[J]. Medicine (Baltimore),2008,87(6):345-364.
[148]Erkan D, Lockshin M D. New approaches for managing antiphospholipid syndrome.[J]. Nat Clin Pract Rheumatol,2009,5(3):160-170.
[149]Erre G L, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome:a case report and a review of literature.[J]. Lupus,2008,17(1):50-55.
[150]Berman J, Girardi G, Salmon J E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.[J].J Immunol,2005,174(1):485-490.
[151]廖再成,张伟霞,倪明军.卡介菌多糖、核酸注射液治疗反复自然流产的免疫学变化[J].南华大学学报(医学版),2008(4).
[152]郭亚南,文海泉,张桂英,等.卡介菌多糖核酸对二硝基氯苯诱导的Nc/Nga小鼠特应性皮炎样皮损的影响[J].中华皮肤科杂志,2010,43(7)：497-500.
[153]陈兴平,李永喜,邓云华,等.卡介菌多糖核酸对免疫抑制小鼠T淋巴细胞亚群的影响[J].华中科技大学学报(医学版),2002(3)：336-338.
[154]苗晋锋,马海田,贾雪波,等.卡介菌多糖核酸缓解内毒素诱发大鼠乳腺炎的机制研究[J].中国农业科学,2010(18)：3869-3875.
[2]Hughes G R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant[J]. Br Med J (Clin Res Ed),1983,287(6399):1088-1089.
[3]Wilson W A, Gharavi A E, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop.[J]. Arthritis Rheum,1999,42(7):1309-1311.
[4]George J, Blank M, Levy Y, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome[J]. Circulation,1998,97(9):900-906.
[5]Pierangeli S S, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models[J]. Thromb Haemost,2000,84(3):388-395.
[6]Blank M, Shoenfeld Y, Cabilly S, et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides[J]. Proc Natl Acad Sci U S A,1999,96(9):5164-5168.
[7]Pierangeli S S, Liu S W, Anderson G, et al. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies[J]. Circulation,1996,94(7):1746-1751.
[8]Miyakis S, Lockshin M D, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost,2006,4(2):295-306.
[9]Tripodi A, de Groot P G, Pengo V. Antiphospholipid syndrome:laboratory detection, mechanisms of action and treatment[J]. J Intern Med,2011,270(2):110-122.
[10]Mehdi A A, Uthman I, Khamashta M. Antiphospholipid syndrome:pathogenesis and a window of treatment opportunities in the future[J]. Eur J Clin Invest,2010,40(5):451-464.
[11]Ornoy A, Yacobi S, Matalon S T, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture[J]. Lupus,2003,12(7):573-578.
[12]Ernest J M, Marshburn P B, Kutteh W H. Obstetric antiphospholipid syndrome: an update on pathophysiology and management J]. Semin Reprod Med,2011,29(6):522-539.
[13]黄健,朱付凡,丁依玲,等.106例妊娠血小板减少临床分析[J].湖南医科大学学报,2003,28(5)：544-546.
[14]杨励勤,朱付凡.抗磷脂综合征和前置胎盘的相关性研究[J].实用妇产科杂志,2007,23(4)：223-225.
[15]谭凌,尹爱武,朱付凡.抗心磷脂抗体阳性与流产关系的临床研究[J].中国计划生育学杂志,2004(12).
[16]朱付凡,孙文霞,黄健.抗心磷脂抗体与各类流产的关系[J].湖南医科大学学报,2003,28(1)：70-72.
[17]孙文霞,朱付凡.抗心磷脂抗体在病理妊娠中的意义[J].长治医学院学报,2001,15(3)：166-168.
[18]Mulla M J, Brosens J J, Chamley L W, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway[J]. Am J Reprod Immunol,2009,62(2):96-111.
[19]Sene D, Piette J C, Cacoub P. [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections][J]. Rev Med Interne,2009,30(2):135-141.
[20]Uthman I W, Gharavi A E. Viral infections and antiphospholipid antibodies[J]. Semin Arthritis Rheum,2002,31(4):256-263.
[21]Willis R, Harris E N, Pierangeli S S. Pathogenesis of the Antiphospholipid Syndrome[J]. Semin Thromb Hemost,2012.
[22]Blank M, Asherson R A, Cervera R, et al. Antiphospholipid syndrome infectious origin[J]. J Clin Immunol,2004,24(1):12-23.
[23]Shoenfeld Y, Blank M, Cervera R, et al. Infectious origin of the antiphospholipid syndrome[J]. Ann Rheum Dis,2006,65(1):2-6.
[24]Rojas-Rodriguez J, Garcia-Carrasco M, Ramos-Casals M, et al. Catastrophic antiphospholipid syndrome:clinical description and triggering factors in 8 patients [J]. J Rheumatol,2000,27(1):238-240.
[25]Undas A, Swadzba J, Undas R, et al. [Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome][J]. Pol Arch Med Wewn,1998,100(6):556-560.
[26]Fu B D, Yamawaki H, Okada M, et al. Vaspin can not inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells[J]. J Vet Med Sci,2009,71(9):1201-1207.
[27]Chen H W, Lin A H, Chu H C, et al. Inhibition of TNF-alpha-Induced Inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway[J]. J Nat Prod,2011,74(11):2408-2413.
[28]Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells[J]. Atherosclerosis,2012,221(2):375-382.
[29]Liu X, Pan L, Wang X, et al. Leonurine protects against tumor necrosis factor-alpha-mediated inflammation in human umbilical vein endothelial cells[J]. Atherosclerosis,2012,222(1):34-42.
[30]Lee Y R, Kim K M, Jeon B H, et al. The n-butanol fraction of Naematoloma sublateritium suppresses the inflammatory response through downregulation of NF-kappaB in human endothelial cells[J]. Int J Mol Med,2012,29(5):801-808.
[31]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies[J]. Blood,2003,101(9):3495-3500.
[32]Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies[J]. Arthritis Rheum,2005,52(5):1545-1554.
[33]Vega-Ostertag M E, Ferrara D E, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation[J]. J Thromb Haemost,2007,5(9):1828-1834.
[34]Ma K, Simantov R, Zhang J C, et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II[J]. J Biol Chem,2000,275(20):15541-15548.
[35]Navarro M, Cervera R, Teixido M, et al. Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome:prevalence and isotype distribution[J]. Br J Rheumatol,1996,35(6):523-528.
[36]Cockrell E, Espinola R G, Mccrae K R. Annexin A2:biology and relevance to the antiphospholipid syndrome[J]. Lupus,2008,17(10):943-951.
[37]Satta N, Kruithof E K, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies[J]. Blood,2011,117(20):5523-5531.
[38]Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of beta2-glycoprotein I cross-react with TLR4 inducing a pro-inflammatory phenotype in endothelial cells and monocytes[J]. Blood,2012.
[39]Pierangeli S S, Vega-Ostertag-M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies[J]. Thromb Res,2004,114(5-6):467-476.
[40]Mak A, Cheung M W, Cheak A A, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies:a meta-analysis of randomized controlled trials and meta-regression[J]. Rheumatology (Oxford),2010,49(2):281-288.
[41]Ferrara D E, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells [J]. J Thromb Haemost,2004,2(9):1558-1563.
[42]李桑琳,朱付凡.产科抗磷脂综合征患者血清对脐静脉内皮细胞活化的研究[J].中国优生与遗传杂志,2008(7).
[43]Cohen D, Berger S P, Steup-Beekman G M, et al. Diagnosis and management of the antiphospholipid syndrome[J]. BMJ,2010,340:c2541.
[44]Yetman D L, Kutteh W H. Antiphospholipid antibody panels and recurrent pregnancy loss:prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies [J]. Fertil Steril,1996,66(4):540-546.
[45]Matzner W, Chong P, Xu G, et al. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions [J]. J Reprod Med,1994,39(1):27-30.
[46]Skrzypczak J, Rajewski M, Wirstlein P, et al. [Frequency of antiphospholipid syndrome in women with pregnancy loss in multicenter study in Poland][J]. Ginekol Pol,2011,82(10):749-754.
[47]Giasuddin A S, Mazhar I, Haq A M. Prevalence of anticardiolipin antibody in Bangladeshi patients with recurrent pregnancy loss[J]. Bangladesh Med Res Counc Bull,2010,36(1):10-13.
[48]Simchen M J, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome[J]. Acta Obstet Gynecol Scand,2011,90(12):1428-1433.
[49]Silver R M, Porter T F, van Leeuween I, et al. Anticardiolipin antibodies:clinical consequences of "low titers"[J]. Obstet Gynecol,1996,87(4):494-500.
[50]Levine S R, Salowich-Palm L, Sawaya K L, et al. IgG anticardiolipin antibody titer> 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study[J]. Stroke,1997,28(9):1660-1665.
[51]Erkan D, Barbhaiya M, George D, et al. Moderate versus high-titer persistently anticardiolipin antibody positive patients:are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?[J].Lupus,2010,19(5):613-619.
[52]Christenson L K, Stouffer R L. Isolation and culture of micro vascular endothelial cells from the primate corpus luteum[J]. Biol Reprod,1996,55(6):1397-1404.
[53]姜开余.白细胞介素6的作用与临床应用前景[J].临床肿瘤学杂志,1997(1)：71-73.
[54]Oldstone M B. Molecular mimicry and immune-mediated diseases[J]. FASEB J,1998,12(13):1255-1265.
[55]Karlsen A E, Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity[J]. Semin Immunol,1998,10(1):25-34.
[56]Albert L J, Inman R D. Molecular mimicry and autoimmunity[J]. N Engl J Med,1999,341 (27):2068-2074.
[57]Regner M, Lambert P H. Autoimmunity through infection or immunization?[J]. Nat Immunol,2001,2(3):185-188.
[58]Wucherpfennig K W. Structural basis of molecular mimicry[J]. J Autoimmun,2001,16(3):293-302.
[59]Rauch J, Dieude M, Subang R, et al. The dual role of innate immunity in the antiphospholipid syndrome[J]. Lupus,2010,19(4):347-353.
[60]Pierangeli S S, Gharavi A E, Harris E N. Experimental thrombosis and antiphospholipid antibodies:new insights[J]. J Autoimmun,2000,15(2):241-247.
[61]Takeda K, Kaisho T, Akira S. Toll-like receptors[J]. Annu Rev Immunol,2003,21:335-376.
[62]Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway [J]. Science,2003,301(5633):640-643.
[63]Raschi E, Borghi M O, Grossi C, et al. Toll-like receptors:another player in the pathogenesis of the anti-phospholipid syndrome[J]. Lupus,2008,17(10):937-942.
[64]Marshak-Rothstein A, Ohashi P S. Intricate connections between innate and adaptive autoimmunity [J]. Curr Opin Immunol,2007,19(6):603-605.
[65]Pasare C, Medzhitov R. Toll-like receptors:linking innate and adaptive immunity[J]. Adv Exp Med Biol,2005,560:11-18.
[66]Marshak-Rothstein A, Rifkin I R. Immunologically active autoantigens:the role of toll-like receptors in the development of chronic inflammatory disease[J]. Annu Rev Immunol,2007,25:419-441.
[67]Hurst J, von Landenberg P. Toll-like receptors and autoimmunity [J]. Autoimmun Rev,2008,7(3):204-208.
[68]Chen K, Huang J, Gong W, et al. Toll-like receptors in inflammation, infection and cancer[J]. Int Immunopharmacol,2007,7(10):1271-1285.
[69]Krutzik S R, Ochoa M T, Sieling P A, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy[J]. Nat Med,2003,9(5):525-532.
[70]Triantafilou M, Gamper F G, Haston R M, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting[J]. J Biol Chem,2006,281(41):31002-31011.
[71]Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts [J]. Arthritis Rheum,2007,56(8):2687-2697.
[72]Meroni P L, Raschi E, Testoni C, et al. Innate immunity in the antiphospholipid syndrome:role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies[J]. Autoimmun Rev,2004,3(7-8):510-515.
[73]Lopez-Pedrera C, Buendia P, Cuadrado M J, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway [J]. Arthritis Rheum,2006,54(1):301-311.
[74]Pierangeli S S, Vega-Ostertag M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies[J]. Thromb Res,2004,114(5-6):467-476.
[75]Doring Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8[J]. Immunobiology,2010,215(3):230-241.
[76]Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-lbeta and caspase-1 in monocytes and dendritic cells[J]. Immunobiology,2009,214(8):683-691.
[77]Satta N, Dunoyer-Geindre S, Reber G, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies[J]. Blood,2007,109(4):1507-1514.
[78]宁云山,姜德建,刘珊珊.卡介苗及卡介菌多糖核酸提取物的免疫调节作用及临床应用[J].中国生物制品学杂志,2008(1)：74-77.
[79]刘光辉,祝戎飞.卡介菌多糖核酸对NF-κB的活化调控[J].中国医院药学杂 志,2005(4)：308-310.
[80]李永喜,陈兴平,邓云华,等.卡介菌多糖核酸对正常小鼠T淋巴细胞亚群的影响[J].青岛大学医学院学报,2004(4).
[81]刘光辉,祝戎飞.卡介菌多糖核酸对NF-κB的活化调控[J].中国医院药学杂志,2005(4)：308-310.
[82]Satta N, Kruithof E K, Reber G, et al. Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides[J]. Mol Immunol,2008,46(1):145-157.
[1]Hughes G R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.[J]. Br Med J (Clin Res Ed),1983,287(6399):1088-1089.
[2]Wilson W A, Gharavi A E, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop.[J]. Arthritis Rheum,1999,42(7):1309-1311.
[3]Miyakis S, Lockshin M D, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).[J]. J Thromb Haemost,2006,4(2):295-306.
[4]Sinico R A, Di Toma L, Sabadini E, et al. Catastrophic antiphospholipid syndrome:report of 4 cases.[J]. J Nephrol,2007,20(6):739-744.
[5]Cervera R, Font J, Gomez-Puerta J A, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.[J]. Ann Rheum Dis,2005,64(8):1205-1209.
[6]Asherson R A, Cervera R, de Groot P G, et al. Catastrophic antiphospholipid syndrome:international consensus statement on classification criteria and treatment guidelines.[J]. Lupus,2003,12(7):530-534.
[7]Cervera R, Piette J C, Font J, et al. Antiphospholipid syndrome:clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.[J]. Arthritis Rheum,2002,46(4):1019-1027.
[8]Tektonidou M G, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome:association with clinical, laboratory, and brain magnetic resonance imaging findings. [J]. Arch Intern Med,2006,166(20):2278-2284.
[9]Cuadrado M J, Khamashta M A, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.[J]. Medicine (Baltimore),2000,79(1):57-68.
[10]Sanna G, Bertolaccini M L, Cuadrado M J, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome.[J]. Rheumatology (Oxford),2003,42(2):200-213.
[11]Branch D W, Khamashta M A. Antiphospholipid syndrome:obstetric diagnosis, management, and controversies.[J]. Obstet Gynecol,2003,101(6):1333-1344.
[12]Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.[J]. BMJ,2005,330(7491):565.
[13]Ruiz-Irastorza G, Khamashta M A. Antiphospholipid syndrome in pregnancy.[J]. Rheum Dis Clin North Am,2007,33(2):287-297.
[14]Opatrny L, David M, Kahn S R, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease:a metaanalysis.[J]. J Rheumatol,2006,33(11):2214-2221.
[15]Nodler J, Moolamalla S R, Ledger E M, et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes:analysis of a population-based hospital dataset.[J]. BMC Pregnancy Childbirth,2009,9:11.
[16]Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome:recommendations for treatment. Committee consensus report.[J]. Lupus,2003,12(7):518-523.
[17]Tektonidou M G, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies:prevalence, clinical associations, and long-term outcome.[J]. Arthritis Rheum,2004,50(8):2569-2579.
[18]Amigo M C, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome.[J]. J Rheumatol,1992,19(8):1181-1185.
[19]Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome.[J]. Blood Rev,2008,22(4):187-194.
[20]Blume J E, Miller C C. Antiphospholipid syndrome:a review and update for the dermatologist.[J]. Cutis,2006,78(6):409-415.
[21]Pierangeli S S, Chen P P, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome:pathogenic mechanisms. [J]. Semin Thromb Hemost,2008,34(3):236-250.
[22]Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.[J]. Blood,2003,101(1):157-162.
[23]Haupt H, Schwick H G, Storiko K. [On a hereditary beta-2-glycoprotein I deficiency]. [J]. Humangenetik,1968,5(4):291-293.
[24]Makatsariya A, Asherson R A, Bitsadze V, et al. Catastrophic antiphospholipid (Asherson's) syndrome and genetic thrombophilic disorders in obstetrics. [J]. Autoimmun Rev,2006,6(2):89-93.
[25]Agar C, van Os G M, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations:implications for our understanding of the antiphospholipid syndrome.[J]. Blood,2010,116(8):1336-1343.
[26]Matsuura E, Igarashi Y, Yasuda T, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.[J]. J Exp Med,1994,179(2):457-462.
[27]de Laat B, Derksen R H, Urbanus R T, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.[J]. Blood,2005,105(4):1540-1545.
[28]Matsuura E, Inagaki J, Kasahara H, et al. Proteolytic cleavage of beta(2)-glycoprotein I:reduction of antigenicity and the structural relationship.[J]. Int Immunol,2000,12(8):1183-1192.
[29]Oosting J D, Derksen R H, Bobbink I W, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S:an explanation for their pathogenic mechanism?[J]. Blood,1993,81(10):2618-2625.
[30]Hurtado V, Montes R, Gris J C, et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death.[J]. Blood,2004,104(5):1369-1374.
[31]Oosting J D, Preissner K T, Derksen R H, et al. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro.[J]. Br J Haematol,1993,85(4):761-768.
[32]Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. [J]. Blood,1998,91 (6):1999-2004.
[33]Marciniak E, Romond E H. Impaired catalytic function of activated protein C:a new in vitro manifestation of lupus anticoagulant. [J]. Blood,1989,74(7):2426-2432.
[34]Boyanovski B, Russeva M, Dobreva G, et al. Protein C Activity in Patients with Antiphospholipid Syndrome.[J]. J Clin Rheumatol,2000,6(5):239-243.
[35]Ruiz-Arguelles G J, Ruiz-Arguelles A, Deleze M, et al. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin.[J]. J Rheumatol,1989,16(3):381-383.
[36]Angles-Cano E, Guillin M C. Antiphospholipid antibodies and the coagulation cascade.[J]. Rheum Dis Clin North Am,2001,27(3):573-586.
[37]Roubey R A. Autoantibodies to phospholipid-binding plasma proteins:a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies.[J]. Blood,1994,84(9):2854-2867.
[38]Macko R F, Ameriso S F, Gruber A, et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. [J]. Stroke,1996,27(11):2005-2011.
[39]Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.[J]. Thromb Haemost,2002,88(5):716-722.
[40]Tomas J F, Alberca I, Tabernero M D, et al. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.[J]. J Rheumatol,1998,25(1):57-62.
[41]Atsumi T, Khamashta M A, Ames P R, et al. Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system.[J]. Lupus,1997,6(4):358-364.
[42]Gris J C, Toulon P, Brun S, et al. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection.[J]. Thromb Haemost,1996,76(1):38-45.
[43]Merrill J T, Zhang H W, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies:beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein.[J]. Thromb Haemost,1999,81(5):748-757.
[44]Ames P R, Tommasino C, Iannaccone L, et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. [J]. Thromb Haemost,1996,76(2):190-194.
[45]Jurado M, Paramo J A, Gutierrez-Pimentel M, et al. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.[J]. Thromb Haemost,1992,68(5):516-520.
[46]Ieko M, Sawada K I, Koike T, et al. The putative mechanism of thrombosis in antiphospholipid syndrome:impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. [J]. Semin Thromb Hemost,1999,25(5):503-507.
[47]Ieko M, Ichikawa K, Atsumi T, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis.[J]. Semin Thromb Hemost,2000,26(1):85-90.
[48]Varela F, Andersson A, Dietrich G, et al. Population dynamics of natural antibodies in normal and autoimmune individuals.[J]. Proc Natl Acad Sci U S A,1991,88(13):5917-5921.
[49]Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome.[J]. Br J Haematol,2000,108(4):871-875.
[50]Takeuchi R, Atsumi T, Ieko M, et al. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies:possible mechanism for thrombosis in patients with antiphospholipid syndrome. [J]. Br J Haematol,2002,119(3):781-788.
[51]Takeya H, Mori T, Gabazza E C, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.[J]. J Clin Invest,1997,99(9):2260-2268.
[52]Rus H G, Niculescu F I, Shin M L. Role of the C5b-9 complement complex in cell cycle and apoptosis.[J]. Immunol Rev,2001,180:49-55.
[53]Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.[J]. J Clin Invest,2003,112(11):1644-1654.
[54]Girardi G, Redecha P, Salmon J E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.[J]. Nat Med,2004,10(11):1222-1226.
[55]Holers V M, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.[J]. J Exp Med,2002,195(2):211-220.
[56]Ikematsu W, Luan F L, La Rosa L, et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice.[J]. Arthritis Rheum,1998,41(6):1026-1039.
[57]Thurman J M, Kraus D M, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.[J], Mol Immunol,2005,42(1):87-97.
[58]Pierangeli S S, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.[J]. Arthritis Rheum,2005,52(7):2120-2124.
[59]Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.[J]. J Immunol,2006,177(7):4794-4802.
[60]Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome.[J]. Ann Rheum Dis,2009,68(6):1030-1035.
[61]Davis W D, Brey R L. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.[J]. Clin Exp Rheumatol,1992,10(5):455-460.
[62]Nachman R L, Silverstein R. Hypercoagulable states.[J]. Ann Intern Med,1993,119(8):819-827.
[63]Romay-Penabad Z, Montiel-Manzano M G, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.[J]. Blood,2009,114(14):3074-3083.
[64]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. [J]. Blood,2003,101(9):3495-3500.
[65]Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies.[J]. Arthritis Rheum,2005,52(5):1545-1554.
[66]Vega-Ostertag M E, Ferrara D E, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. [J]. J Thromb Haemost,2007,5(9):1828-1834.
[67]Alard J E, Gaillard F, Daridon C, et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I.[J]. J Immunol,2010,185(3):1550-1557.
[68]Satta N, Kruithof E K, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies.[J]. Blood,2011,117(20):5523-5531.
[69]Simantov R, Lasala J M, Lo S K, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. [J]. J Clin Invest,1995,96(5):2211-2219.
[70]Gharavi A E, Pierangeli S S, Colden-Stanfield M, et al. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro.[J]. J Immunol,1999,163(5):2922-2927.
[71]Pierangeli S S, Espinola R G, Liu X, et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.[J]. Circ Res,2001,88(2):245-250.
[72]Atsumi T, Khamashta M A, Haworth R S, et al. Arterial disease and thrombosis in the antiphospholipid syndrome:a pathogenic role for endothelin 1.[J]. Arthritis Rheum,1998,41(5):800-807.
[73]Blann A D, Miller J P, Mccollum C N. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia.[J]. Atherosclerosis,1997,132(2):151-156.
[74]Lindsey N J, Dawson R A, Henderson F I, et al. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome.[J]. Br J Rheumatol,1993,32(2):123-126.
[75]Levy Y, Shenkman B, Tamarin I, et al. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. [J]. Arthritis Rheum,2005,52(12):4011-4017.
[76]van Baal W M, Kenemans P, Emeis J J, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. [J]. Fertil Steril,1999,71(4):663-670.
[77]Sadler J E. Thrombomodulin structure and function. [J]. Thromb Haemost,1997,78(1):392-395.
[78]Haruta K, Kobayashi S, Hirose S, et al. Monoclonal anti-cardiolipin antibodies from New Zealand Black x New Zealand White F1 mice react to thrombomodulin.[J]. J Immunol,1998,160(1):253-258.
[79]Ichikawa K, Suzuki T, Hashimoto Y, et al. Monoclonal autoantibodies to cardiolipin derived from SLE mice.[J]. Lupus,1992,1(4):239-247.
[80]Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies.[J]. Int Immunol,2004,16(11):1633-1641.
[81]Lopez-Pedrera C, Buendia P, Cuadrado M J, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.[J]. Arthritis Rheum,2006,54(1):301-311.
[82]Meroni P L, Raschi E, Testoni C, et al. Innate immunity in the antiphospholipid syndrome:role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies.[J]. Autoimmun Rev,2004,3(7-8):510-515.
[83]Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. [J]. Blood,2003,101(9):3495-3500.
[84]Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. [J]. Arthritis Rheum,2007,56(8):2687-2697.
[85]Doling Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8.[J]. Immunobiology,2010,215(3):230-241.
[86]Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-lbeta and caspase-1 in monocytes and dendritic cells.[J]. Immunobiology,2009,214(8):683-691.
[87]Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. [J]. J Immunol,1994,153(3):1328-1332.
[88]Cuadrado M J, Lopez-Pedrera C, Khamashta M A, et al. Thrombosis in primary antiphospholipid syndrome:a pivotal role for monocyte tissue factor expression. [J]. Arthritis Rheum,1997,40(5):834-841.
[89]Segal J, Kickler T, Petri M. Tissue factor activity in patients with systemic lupus erythematosus:association with disease activity. [J]. J Rheumatol,2000,27(12):2827-2832.
[90]Campbell A L, Pierangeli S S, Wellhausen S, et al. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. [J]. Thromb Haemost,1995,73(3):529-534.
[91]Arvieux J, Roussel B, Pouzol P, et al. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I.[J]. Thromb Haemost,1993,70(2):336-341.
[92]Khamashta M A, Harris E N, Gharavi A E, et al. Immune mediated mechanism for thrombosis:antiphospholipid antibody binding to platelet membranes.[J]. Ann Rheum Dis,1988,47(10):849-854.
[93]de Groot P G, van Lummel M, Pennings M, et al. Beta2-glycoprotein I and LDL-receptor family members.[J].Thromb Res,2004,114(5-6):455-459.
[94]Pierangeli S S, Vega-Ostertag M, Harris E N. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells:a pathway to targeted therapies.[J]. Thromb Res,2004,114(5-6):467-476.
[95]Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.[J]. Arthritis Rheum,2006,54(8):2558-2567.
[96]Reverter J C, Tassies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.[J]. Arthritis Rheum,1998,41(8):1420-1427.
[97]Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.[J]. N Engl J Med,2002,346(10):752-763.
[98]Robbins D L, Leung S, Miller-Blair D J, et al. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome.[J]. J Rheumatol,1998,25(1):51-56.
[99]Redecha P, Tilley R, Tencati M, et al. Tissue factor:a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury.[J], Blood,2007,110(7):2423-2431.
[100]Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.[J]. J Clin Invest,2003,112(11):1644-1654.
[101]Di Simone N, Marana R, Castellani R, et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation.[J]. Arthritis Rheum,2010,62(5):1504-1512.
[102]Mulla M J, Brosens J J, Chamley L W, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.[J]. Am J Reprod Immunol,2009,62(2):96-111.
[103]Yu P, Passam F H, Yu D M, et al. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. [J]. J Thromb Haemost,2008,6(7):1215-1223.
[104]Merten M,Motamedy S, Ramamurthy S, et al. Sulfatides:targets for anti-phospholipid antibodies.[J]. Circulation,2003,108(17):2082-2087.
[105]Delgado A J, Mason L J, Ames P R, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model.[J]. Rheumatology (Oxford),2005,44(10):1238-1244.
[106]Rao L V, Hoang A D, Rapaport S I. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid.[J]. Blood,1996,88(11):4173-4182.
[107]Dombroski D, Balasubramanian K, Schroit A J. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice.[J]. J Autoimmun,2000,14(3):221-229.
[108]Salemink I, Blezer R, Willems G M, et al. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor.[J]. Thromb Haemost,2000,84(4):653-656.
[109]Brachvogel B, Dikschas J, Moch H, et al. Annexin A5 is not essential for skeletal development.[J]. Mol Cell Biol,2003,23(8):2907-2913.
[110]Kearon C, Kahn S R, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).[J]. Chest,2008,133(6 Suppl):454S-545S.
[111]Tripodi A, de Groot P G, Pengo V. Antiphospholipid syndrome:laboratory detection, mechanisms of action and treatment. [J]. J Intern Med,2011,270(2):110-122.
[112]Prandoni P, Prins M H, Lensing A W, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis:a randomized trial.[J]. Ann Intern Med,2009,150(9):577-585.
[113]Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy.[J]. N Engl J Med,2006,355(17):1780-1789.
[114]Cosmi B, Legnani C, Tosetto A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism:the extended follow-up of the PROLONG study.[J]. J Thromb Thrombolysis,2009,28(4):381-388.
[115]Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).[J]. J Thromb Haemost,2005,3(5):848-853.
[116]Crowther M A, Ginsberg J S, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.[J]. N Engl J Med,2003,349(12):1133-1138.
[117]Khamashta M A, Cuadrado M J, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. [J]. N Engl J Med,1995,332(15):993-997.
[118]Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS).[J].Neurology,1997,48(l):91-94.
[119]Lim W, Crowther M A, Eikelboom J W. Management of antiphospholipid antibody syndrome:a systematic review.[J]. JAMA,2006,295(9):1050-1057.
[120]Ruiz-Irastorza G, Hunt B J, Khamashta M A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.[J]. Arthritis Rheum,2007,57(8):1487-1495.
[121]Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome.[J]. Lancet,2010,376(9751):1498-1509.
[122]Mak A, Cheung M W, Cheak A A, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies:a meta-analysis of randomized controlled trials and meta-regression.[J]. Rheumatology (Oxford),2010,49(2):281-288.
[123]Ziakas P D, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss:a systematic review and meta-analysis.[J]. Obstet Gynecol,2010,115(6):1256-1262.
[124]Noble L S, Kutteh W H, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss:prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.[J]. Fertil Steril,2005,83(3):684-690.
[125]Bates S M, Greer I A, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).[J]. Chest,2008,133(6 Suppl):844S-886S.
[126]Carmona F, Font J, Azulay M, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies:a multivariate analysis.[J]. Am J Reprod Immunol,2001,46(4):274-279.
[127]Silver R K, Macgregor S N, Sholl J S, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. [J]. Am J Obstet Gynecol,1993,169(6):1411-1417.
[128]Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome.[J]. Rheumatology (Oxford),2000,39(4):421-426.
[129]Branch D W, Peaceman A M, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.[J]. Am J Obstet Gynecol,2000,182(1 Pt 1):122-127.
[130]Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies:a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin.[J]. Am J Reprod Immunol,2001,45(3):174-179.
[131]Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.[J]. Arthritis Rheum,2003,48(3):728-731.
[132]Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.[J]. Cochrane Database Syst Rev,2005(2):D2859.
[133]Huong D L, Wechsler B, Bletry O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome.[J]. J Rheumatol,2001,28(9):2025-2030.
[134]Antiplatelet agents for prevention of pre-eclampsia and its consequences:a systematic review and individual patient data meta-analysis.[J]. BMC Pregnancy Childbirth,2005,5(1):7.
[135]Ruiz-Irastorza G, Khamashta M A. Lupus and pregnancy:ten questions and some answers.[J]. Lupus,2008,17(5):416-420.
[136]Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome.[J]. Lancet,2010,376(9751):1498-1509.
[137]Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. [J]. Arthritis Res Ther,2006,8(3):209.
[138]Ferrara D E, Liu X, Espinola R G, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model.[J]. Arthritis Rheum,2003,48(11):3272-3279.
[139]Meroni P L, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype.[J]. Arthritis Rheum,2001,44(12):2870-2878.
[140]Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome?[J]. Ann N Y Acad Sci,2009,1173:736-745.
[141]Pierangeli S S, Vega-Ostertag M E, Gonzalez E B. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. [J]. Expert Rev Mol Med,2007,9(30):1-15.
[142]Rand J H, Wu X X, Quinn A S, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.[J]. Blood,2008,112(5):1687-1695.
[143]-Espinola R G, Pierangeli S S, Gharavi A E, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.[J]. Thromb Haemost,2002,87(3):518-522.
[144]Ehrnthaller C, Ignatius A, Gebhard F, et al. New insights of an old defense system:structure, function, and clinical relevance of the complement system.[J]. Mol Med,2011,17(3-4):317-329.
[145]Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab.[J]. Br J Haematol,2010,149(3):446-450.
[146]Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. [J]. Arthritis Rheum,2008,58(9):2824-2834.
[147]Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.[J]. Medicine (Baltimore),2008,87(6):345-364.
[148]Erkan D, Lockshin M D. New approaches for managing antiphospholipid syndrome.[J]. Nat Clin Pract Rheumatol,2009,5(3):160-170.
[149]Erre G L, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome:a case report and a review of literature.[J]. Lupus,2008,17(1):50-55.
[150]Berman J, Girardi G, Salmon J E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss.[J].J Immunol,2005,174(1):485-490.
[151]廖再成,张伟霞,倪明军.卡介菌多糖、核酸注射液治疗反复自然流产的免疫学变化[J].南华大学学报(医学版),2008(4).
[152]郭亚南,文海泉,张桂英,等.卡介菌多糖核酸对二硝基氯苯诱导的Nc/Nga小鼠特应性皮炎样皮损的影响[J].中华皮肤科杂志,2010,43(7)：497-500.
[153]陈兴平,李永喜,邓云华,等.卡介菌多糖核酸对免疫抑制小鼠T淋巴细胞亚群的影响[J].华中科技大学学报(医学版),2002(3)：336-338.
[154]苗晋锋,马海田,贾雪波,等.卡介菌多糖核酸缓解内毒素诱发大鼠乳腺炎的机制研究[J].中国农业科学,2010(18)：3869-3875.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |